HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

Neutralizing antibodies to HIV-1 induced by immunization

(2013) Laura E. McCoy et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies

(2013) Ron Diskin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

(2013) Hua-Xin Liao et al.   NATURE

Report of the Cent Gardes HIV Vaccine Conference the B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5–7 November 2012

(2013) Marc P. Girard et al.   VACCINE

The Antibody Response against HIV-1

(2013) J. Overbaugh et al.   Cold Spring Harbor Perspectives in Medicine

HIV-1 Antiretroviral Drug Therapy

(2013) E. J. Arts et al.   Cold Spring Harbor Perspectives in Medicine

A Blueprint for HIV Vaccine Discovery

(2012) Dennis R. Burton et al.   Cell Host & Microbe

Redefining the Viral Reservoirs that Prevent HIV-1 Eradication

(2012) Evelyn Eisele et al.   IMMUNITY

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

(2012) Florian Klein et al.   NATURE

Humanized Mice Recapitulate Key Features of HIV-1 Infection: A Novel Concept Using Long-Acting Anti-Retroviral Drugs for Treating HIV-1

(2012) Marc Nischang et al.   PLoS One

Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection

(2012) Elizabeth Hamlyn et al.   PLoS One

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

(2012) B. Moldt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

(2012) H. Mouquet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed Antibodies

(2012) Irene A. Abela et al.   PLoS Pathogens

Generation of HIV Latency in Humanized BLT Mice

(2011) P. W. Denton et al.   JOURNAL OF VIROLOGY

The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection

(2011) E. S. Gray et al.   JOURNAL OF VIROLOGY

Antibody-based protection against HIV infection by vectored immunoprophylaxis

(2011) Alejandro B. Balazs et al.   NATURE

Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy

(2011) Alex Sigal et al.   NATURE

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

(2011) Jason S. McLellan et al.   NATURE

Broad neutralization coverage of HIV by multiple highly potent antibodies

(2011) Laura M. Walker et al.   NATURE

Prospects for an HIV vaccine: leading B cells down the right path

(2011) Susan Moir et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses

(2011) Hugo Mouquet et al.   PLoS One

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

(2011) X. Wu et al.   SCIENCE

Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design

(2011) R. Diskin et al.   SCIENCE

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

(2011) J. F. Scheid et al.   SCIENCE

The Role of Antibodies in HIV Vaccines

(2010) John R. Mascola et al.   Annual Review of Immunology

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

(2010) Jean-Michel Molina et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Virological Synapse-Mediated Spread of Human Immunodeficiency Virus Type 1 between T Cells Is Sensitive to Entry Inhibition

(2010) N. Martin et al.   JOURNAL OF VIROLOGY

Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1

(2010) Mei-Yun Zhang et al.   mAbs

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

(2010) X. Wu et al.   SCIENCE

Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viremia with Reverse Transcriptase and Integrase Inhibitors, CD4+ T-Cell Recovery, and Viral Rebound upon Interruption of Therapy in a New Model for HIV Treatment in the Humanized Rag2-/- c-/- Mouse

(2009) S. K. Choudhary et al.   JOURNAL OF VIROLOGY

Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

(2009) M. D. Simek et al.   JOURNAL OF VIROLOGY

Systematic Evaluation of AAV Vectors for Liver directed Gene Transfer in Murine Models

(2009) Lili Wang et al.   MOLECULAR THERAPY

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

(2009) Johannes F. Scheid et al.   NATURE

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

(2009) Philip R Johnson et al.   NATURE MEDICINE

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL